OSTEOCIS Kit for radiopharmaceutical preparation Ref.[27900] Active ingredients: Technetium ⁹⁹ᵐTc oxidronic acid

Distribution

Intravenously administered technetium (^99mTc) oxidronate is rapidly distributed throughout the extracellular space.

Organ uptake

Skeletal uptake begins almost immediately and proceeds rapidly. 30 minutes post injection 10% of the initial dose is still present in whole blood. At 1 hour, 2 hours, 3 hours and 4 hours after injection these values are resp. 5%, 3%, 1.5% and 1%.

Elimination

Clearance from the body takes place via the kidneys. Of the administered activity about 30% is cleared within the first hour, 48% within two hours and 60% within 6 hours.

Toxicological studies with rats have demonstrated that with a single intravenous injection of 30 mg/kg no deaths were observed. Minimal liver abnormalities were seen at this dose level. Toxicity with repeated administration of 10 mg/kg/day over 14 days in rats was not observed. In the dog, after repeated administration of 3 and 10 mg/kg/day over 14 days, histological changes in the liver (microgranuloma) were observed together with long-lasting indurations at the site of injection. This agent is not intended for regular or continuous administration.

Mutagenicity studies, toxicity to reproduction and development studies and long-term carcinogenicity studies have not been carried out.